Rapid Diagnostic Test Kits Market Report 2026

The rapid diagnostic test kits market size has grown strongly in recent years. It will grow from $24.08 billion in 2025 to $25.59 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to increasing burden of infectious diseases, expansion of decentralized healthcare delivery, rising demand for quick diagnostic results, growth in outpatient and homecare testing, availability of lateral flow and immunoassay technologies.

The rapid diagnostic test kits market size is expected to see strong growth in the next few years. It will grow to $32.22 billion in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing investments in rapid diagnostic innovation, rising adoption of self-testing kits, expansion of infectious disease surveillance programs, growing demand for affordable diagnostics in emerging markets, increasing integration of digital readout technologies. Major trends in the forecast period include increasing adoption of point-of-care testing solutions, rising demand for multiplex rapid test kits, growing use of home-based diagnostic testing, expansion of portable and disposable test formats, enhanced focus on early disease detection.

The increasing prevalence of infectious diseases is expected to drive the growth of the rapid diagnostic test kits market going forward. Infectious diseases are illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites that can spread directly or indirectly from one person to another. The rising prevalence of infectious diseases is fueled by antimicrobial resistance and evolving pathogen strains, as widespread antibiotic use has resulted in drug-resistant bacterial infections, while viruses continue to mutate, producing new variants that evade existing immunity and require updated detection methods. The growing prevalence of infectious diseases supports greater adoption of point-of-care testing devices, which enable rapid pathogen identification, allowing healthcare providers to quickly diagnose infections, initiate appropriate treatment, and implement timely infection control measures. For instance, in March 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, tuberculosis cases rose from 8,320 in 2022 to 9,615 in 2023, representing an increase of 1,295 cases. Therefore, the increasing prevalence of infectious diseases is driving growth in the rapid diagnostic test kits market.

Major companies in the rapid diagnostic test kits market are focusing on developing innovative solutions, such as saliva-based pregnancy test kits, to gain a competitive advantage. Saliva-based pregnancy test kits are diagnostic tools that detect pregnancy by analyzing a woman’s saliva for hormonal changes, particularly human chorionic gonadotropin (hCG), which is produced during pregnancy. For instance, in February 2023, Abingdon Health plc, a UK-based near-patient diagnostics company, launched Salistick, the first rapid saliva-based pregnancy test in the UK and Ireland. This innovation provides a cleaner, more convenient alternative to traditional urine-based tests, detecting the pregnancy hormone β-hCG in saliva and enabling early pregnancy detection anytime, anywhere, while also offering a more personal and shareable testing experience.

In June 2023, Avacta Group, a UK-based biotechnology company, acquired Coris Bioconcept SRL for $8.42 million. Through this acquisition, Avacta aims to expand its diagnostics portfolio by integrating Coris’s rapid test products and expertise, enhancing capabilities in both centralized laboratory and decentralized point-of-care testing, while strengthening its position in the growing markets for infectious disease and antimicrobial resistance diagnostics. Coris Bioconcept SRL is a Belgium-based company providing rapid diagnostic kits for the detection of human respiratory, gastroenteric, and blood-borne pathogens.

Major companies operating in the rapid diagnostic test kits market are F Hoffmann La Roche Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company, Hologic Inc, bioMerieux SA, QuidelOrtho Corporation, Bio Rad Laboratories Inc, QIAGEN NV, Cepheid Inc, OraSure Technologies Inc, Nova Biomedical Corporation, Sekisui Diagnostics LLC, EKF Diagnostics Holdings plc, Trinity Biotech plc, ACON Laboratories Inc, Fluxergy LLC, Lumos Diagnostics Holdings Limited, Abingdon Health plc, Abionic SA.

North America was the largest region in the rapid diagnostic test kits market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rapid diagnostic test kits market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rapid diagnostic test kits market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the rapid diagnostic test kits market by increasing costs of imported reagents, membranes, antibodies, plastic casings, and electronic readers used in test kit manufacturing. Diagnostic laboratories and healthcare providers in North America and Europe are most affected due to dependence on imported consumables, while Asia-Pacific faces higher production costs for export-oriented test kits. These tariffs are raising unit prices and impacting supply chain stability. However, they are also driving localization of reagent manufacturing, expansion of domestic kit assembly, and diversification of supplier networks to reduce long-term dependency.

The rapid diagnostic test kits market research report is one of a series of new reports that provides rapid diagnostic test kits market statistics, including rapid diagnostic test kits industry global market size, regional shares, competitors with a rapid diagnostic test kits market share, detailed rapid diagnostic test kits market segments, market trends and opportunities, and any further data you may need to thrive in the rapid diagnostic test kits industry. This rapid diagnostic test kits market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rapid diagnostic test kits are portable, easy-to-use medical tools designed to quickly detect the presence or absence of specific diseases, infections, or health conditions. They often deliver results within minutes, making them valuable for point-of-care testing, early diagnosis, and immediate treatment decisions in both clinical and remote settings.

The primary product types of rapid diagnostic test kits include antigen test kits, antibody test kits, nucleic acid test kits, and multi-analyte test kits. Antigen test kits are diagnostic tools that detect specific proteins from a pathogen, such as a virus, to rapidly identify an active infection. These kits are categorized by technology into fluorescent immunoassay, enzyme-linked immunosorbent assay (ELISA), colloidal gold-based tests, and lateral flow assays. They are also divided by application into infectious disease testing, cardiology testing, oncology testing, pregnancy and fertility testing, toxicology testing, glucose monitoring, and others, serving end users such as hospitals, diagnostic laboratories, homecare settings, and pharmacies.

The rapid diagnostic test kits market consists of sales of influenza test kits, malaria test kits, pregnancy test kits, glucose monitoring kits, hepatitis test kits, and dengue test kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.